ACADIA Pharmaceuticals Inc
ACADHealthcare|Biotechnology|USA
$26.22
-0.19 (-0.72%)
DCF (FCF)
$4.73
Tangible Book
$6.67
Graham Number
$18.18
Earnings Power
$5.25
Upcoming Data Readouts (6)
Dec 2026
Est. completion
P2Autism Spectrum Disorder
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
NCT05999240n=30
Jan 2027
Est. completion
Jun 2027
Est. completion
NAStroke Acute
Virtual Reality Rehabilitation for Stroke Patients in the Hospital and at Home.
NCT06864741n=40
Aug 2027
Est. completion
P2Major Depressive Disorder (MDD)
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667n=153
Jan 2028
Est. completion
P2P3Alzheimer's Disease Psychosis
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673n=1,074
Feb 2028
Est. completion
P2Lewy Body Dementia Psychosis
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07029581n=180
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2025
P3
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06173531